Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes

Jan Czyzyk, Octavian Henegariu, Paula Preston-Hurlburt, Raman Baldzizhar, Christine Fedorchuk, Enric Esplugues, Kim Bottomly, Frans K. Gorus, Kevan Herold, Richard A. Flavell

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Intracellular (clade B) OVA-serpin protease inhibitors play an important role in tissue homeostasis by protecting cells from death in response to hypo-osmotic stress, heat shock, and other stimuli. It is not known whether these serpins influence immunological tolerance and the risk for autoimmune diseases.We found that a fraction of young autoimmune diabetes-prone NOD mice had elevated levels of autoantibodies against a member of clade B family known as serpinB13. High levels of anti-serpinB13 Abs were accompanied by low levels of anti-insulin autoantibodies, reduced numbers of islet-associated T cells, and delayed onset of diabetes. Exposure to anti-serpinB13 mAb alone also decreased islet inflammation, and coadministration of this reagent and a suboptimal dose of anti-CD3 mAb accelerated recovery from diabetes. In a fashion similar to that discovered in the NOD model, a deficiency in humoral activity against serpinB13 was associated with early onset of human type 1 diabetes. These findings suggest that, in addition to limiting exposure to proteases within the cell, clade B serpins help to maintain homeostasis by inducing protective humoral immunity.

Original languageEnglish (US)
Pages (from-to)6319-6327
Number of pages9
JournalJournal of Immunology
Volume188
Issue number12
DOIs
StatePublished - Jun 15 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes'. Together they form a unique fingerprint.

Cite this